Virus and antigen purification and conjugation
Disclosed herein are methods of forming compounds and exemplary compounds in the nature of a conjugated compound demonstrating enhanced stability, which in some embodiments comprises a protein and virus particle mixed in a conjugation reaction to form a conjugate mixture, such that the conditions and steps of forming these products allow for unrefrigerated storage for longer time periods than previous approaches, thus making feasible access to such products over a global supply chain.
1. A chemical compound, comprising:
a protein conjugated to a virus particle, and
wherein when the chemical compound is placed in an unrefrigerated environment at a storage temperature for a time period, an integrity or a concentration of the chemical compound at the end of the time period is at least 90% of an initial integrity or an initial concentration of the chemical compound, wherein the time period is at least 42 days a release date of the chemical compound.
2. The chemical compound of claim 1 , wherein the protein is chemically associated with lysine residues on a surface of the virus particle.
3. The chemical compound of claim 1 , wherein the storage temperature is at least 20° C.
4. The chemical compound of claim 1 , wherein the virus particle is a virus.
5. The chemical compound of claim 4 , wherein the virus is an enveloped virus.
6. The chemical compound of claim 4 , wherein the virus is tobacco mosaic virus.
7. The chemical compound of claim 1 , wherein the time period is at least 90 days after the release date of the chemical compound.
8. The chemical compound of claim 1 , wherein the time period is at least 180 days after the release date of the chemical compound.
9. A chemical compound, comprising:
a conjugated protein and a virus wherein the protein is chemically associated with lysine residues on a surface of the virus, and
wherein when the chemical compound is placed in an unrefrigerated environment at a storage temperature for a time period, an integrity or a concentration of the chemical compound at the end of the time period is at least 90% of an initial integrity or an initial concentration of the chemical compound, wherein the time period is at least 42 days a release date of the chemical compound.
10. The chemical compound of claim 9 , wherein the storage temperature is at least 20° C.
11. The chemical compound of claim 9 , wherein the virus is tobacco mosaic virus.
12. The chemical compound of claim 9 , wherein the protein is an antigen.
13. The chemical compound of claim 12 , wherein the antigen is hemagglutinin antigen.
14. The chemical compound of claim 9 , wherein the time period is at least 180 days after the release date of the chemical compound.
15. A chemical compound, comprising:
an antigen and a virus particle wherein the antigen is chemically associated with lysine residues on a surface of the virus particle, and
wherein when placed in an unrefrigerated environment at a storage temperature and after a time period of at least 42 days following a release date of the chemical compound, the chemical compound demonstrates a stability that exceeds a stability of the antigen alone as measured by one or more of antigen concentration, antigen integrity, or antigen potency.
16. The chemical compound of claim 15 , wherein the storage temperature is at least 20° C.
17. The chemical compound of claim 15 , wherein the antigen is hemagglutinin antigen.
18. The chemical compound of claim 15 , where the virus particle is tobacco mosaic virus.
19. The chemical compound of claim 15 , wherein the time period is at least 180 days after the release date of the conjugate mixture.
20. The chemical compound of claim 15 , wherein the measure of stability is antigen concentration, and a difference between the concentration of the conjugate mixture and the concentration of the antigen alone is at least 10%.